Castleark Management’s Medifast MED Stock Holding History

Castleark Management’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-12,065	Closed	-$2.32M	–	351
2021 Q3	$2.32M	Sell	12,065 -21,915	-64%	-$5.39M	0.09%	178
2021 Q2	$9.62M	Buy	33,980 +9,110	+37%	+$2.47M	0.32%	82
2021 Q1	$5.27M	Buy	+24,870	New	+$5.95M	0.19%	132
2020 Q3	–	Sell	-56,720	Closed	-$7.87M	–	366
2020 Q2	$7.87M	Buy	+56,720	New	+$5.21M	0.34%	80
2018 Q3	–	Sell	-38,751	Closed	-$6.21M	–	395
2018 Q2	$6.21M	Sell	38,751 -26,175	-40%	-$3.35M	0.19%	168
2018 Q1	$6.07M	Buy	+64,926	New	+$4.85M	0.19%	163

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Castleark Management's MED Position: Q4 2021 in Review

Castleark Management sold out of Medifast (MED) in Q4 2021, closing a stake of 12,065 shares — an estimated $2.32M sold.

Castleark Management first reported a position in MED in Q1 2018 and held it in 6 quarters. The position peaked at $9.62M in Q2 2021. 297 funds tracked by Wall St. Rank hold MED as of Q4 2021.

Castleark Management reported no remaining Medifast position as of Q4 2021 after selling out during the quarter.
Castleark Management sold 12,065 Medifast shares in Q4 2021, an estimated $2.32M.
Castleark Management first reported a position in Medifast in Q1 2018 and held it in 6 quarters.
Castleark Management's Medifast position peaked at $9.62M in Q2 2021.
297 funds tracked by Wall St. Rank held Medifast as of Q4 2021.

Based on Castleark Management's 13F filing for Q4 2021, filed 16 Feb 2022.